An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10 mg in Subjects With MS.

Trial Profile

An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10 mg in Subjects With MS.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2013

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Acronyms STEADY
  • Most Recent Events

    • 28 May 2013 Data will be presented at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), according to an Acorda Therapeutics media release.
    • 13 Mar 2013 Data was presented at the 65th American Academy of Neurology Annual Meeting (AAN-2013; P04.103), according to an Acorda Therapeutics media release.
    • 30 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top